Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jorge Cortes

Showing results (561-570 of 713) with videos related to

Pageof 72
Sort By:
Antimicrobial Agents and Chemotherapy|December 27, 2005
Open-label, randomized comparison of itraconazole versus caspofungin for prophylaxis in patients with hematologic malignanciesGloria N Mattiuzzi, Gladys Alvarado, Francis J Giles, et al.
Leukemia & Lymphoma|October 4, 2017
Life after ponatinib failure: outcomes of chronic and accelerated phase CML patients who discontinued ponatinib in the salvage settingPrajwal Boddu, Abdul Rashid Shah, Gautam Borthakur, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 5, 2009
Impact of baseline BCR-ABL mutations on response to nilotinib in patients with chronic myeloid leukemia in chronic phaseTimothy Hughes, Giuseppe Saglio, Susan Branford, et al.
Hemasphere|November 15, 2019
Diagnosis and Treatment of Chronic Myelomonocytic Leukemias in Adults: Recommendations From the European Hematology Association and the European LeukemiaNetRaphael Itzykson, Pierre Fenaux, David Bowen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 10, 2005
Phase I study of cloretazine (VNP40101M), a novel sulfonylhydrazine alkylating agent, combined with cytarabine in patients with refractory leukemiaFrancis Giles, Srdan Verstovsek, Deborah Thomas, et al.
Blood|January 10, 2016
Early T-cell precursor acute lymphoblastic leukemia/lymphoma (ETP-ALL/LBL) in adolescents and adults: a high-risk subtypeNitin Jain, Audrey V Lamb, Susan O'Brien, et al.
Clinical Lymphoma, Myeloma & Leukemia|January 19, 2016
A Phase II Study of Coltuximab Ravtansine (SAR3419) Monotherapy in Patients With Relapsed or Refractory Acute Lymphoblastic LeukemiaHagop M Kantarjian, Bruno Lioure, Stella K Kim, et al.
British Journal of Haematology|October 15, 2014
Clinical characteristics and outcomes in patients with acute promyelocytic leukaemia and hyperleucocytosisNaval Daver, Hagop Kantarjian, Guido Marcucci, et al.
Journal of Hematology & Oncology|November 14, 2025
Olutasidenib for mutated IDH1 acute myeloid leukemia: final five-year results from the phase 2 pivotal cohortJorge Cortes, Antonio Curti, Pierre Fenaux, et al.
Blood|January 11, 2003
Experience with alemtuzumab plus rituximab in patients with relapsed and refractory lymphoid malignanciesStefan Faderl, Deborah A Thomas, Susan O'Brien, et al.
Pageof 72

Showing results (561-570 of 713) with videos related to

Sort By:
Pageof 72
Antimicrobial Agents and Chemotherapy|December 27, 2005
Open-label, randomized comparison of itraconazole versus caspofungin for prophylaxis in patients with hematologic malignanciesGloria N Mattiuzzi, Gladys Alvarado, Francis J Giles, et al.
Leukemia & Lymphoma|October 4, 2017
Life after ponatinib failure: outcomes of chronic and accelerated phase CML patients who discontinued ponatinib in the salvage settingPrajwal Boddu, Abdul Rashid Shah, Gautam Borthakur, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 5, 2009
Impact of baseline BCR-ABL mutations on response to nilotinib in patients with chronic myeloid leukemia in chronic phaseTimothy Hughes, Giuseppe Saglio, Susan Branford, et al.
Hemasphere|November 15, 2019
Diagnosis and Treatment of Chronic Myelomonocytic Leukemias in Adults: Recommendations From the European Hematology Association and the European LeukemiaNetRaphael Itzykson, Pierre Fenaux, David Bowen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 10, 2005
Phase I study of cloretazine (VNP40101M), a novel sulfonylhydrazine alkylating agent, combined with cytarabine in patients with refractory leukemiaFrancis Giles, Srdan Verstovsek, Deborah Thomas, et al.
Blood|January 10, 2016
Early T-cell precursor acute lymphoblastic leukemia/lymphoma (ETP-ALL/LBL) in adolescents and adults: a high-risk subtypeNitin Jain, Audrey V Lamb, Susan O'Brien, et al.
Clinical Lymphoma, Myeloma & Leukemia|January 19, 2016
A Phase II Study of Coltuximab Ravtansine (SAR3419) Monotherapy in Patients With Relapsed or Refractory Acute Lymphoblastic LeukemiaHagop M Kantarjian, Bruno Lioure, Stella K Kim, et al.
British Journal of Haematology|October 15, 2014
Clinical characteristics and outcomes in patients with acute promyelocytic leukaemia and hyperleucocytosisNaval Daver, Hagop Kantarjian, Guido Marcucci, et al.
Journal of Hematology & Oncology|November 14, 2025
Olutasidenib for mutated IDH1 acute myeloid leukemia: final five-year results from the phase 2 pivotal cohortJorge Cortes, Antonio Curti, Pierre Fenaux, et al.
Blood|January 11, 2003
Experience with alemtuzumab plus rituximab in patients with relapsed and refractory lymphoid malignanciesStefan Faderl, Deborah A Thomas, Susan O'Brien, et al.
Pageof 72